MAFRuxolitinib Tablet 5 mg, 15 mg, 20 mg
Treatment of patients with:
a) intermediate-1 risk myelofibrosis with severe disease-related symptoms or splenomegaly that are resistant, refractory or intolerant to available therapy; or
b) intermediate-2 or high-risk myelofibrosis with disease-related splenomegaly or symptoms.